文献速递糖尿病

Pandemrix®疫苗接种与TEDDY研究儿童中胰岛自身免疫或1型糖尿病风险增加无关

Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children.
PubMed 文献 · Diabetologia · 2017-10-09

在TEDDY前瞻性队列中,2009年甲型H1N1流感大流行期间瑞典和芬兰3401名遗传高风险儿童中2413名(71%)接种了含角鲨烯的Pandemrix®疫苗;至2016年7月31日,接种组出现至少一种胰岛自身抗体的HR为0.75(95%CI 0.55, 1.03),1型糖尿病HR为0.67(95%CI 0.42, 1.07),均未达统计学显著;芬兰接种儿童胰岛自身免疫和1型糖尿病风险降低,瑞典未见此关联。

要点

  • 接种Pandemrix®疫苗儿童出现至少一种胰岛自身抗体的HR为0.75(95%CI 0.55, 1.03),风险未增加。
  • 接种组1型糖尿病HR为0.67(95%CI 0.42, 1.07),未达统计学显著。
  • 芬兰接种儿童胰岛自身免疫风险降低(HR 0.47 [0.29, 0.75]),瑞典未见此关联。

核心结论

  • 遗传高风险儿童在2009年甲型H1N1流感大流行期间接种Pandemrix®疫苗后,胰岛自身免疫、多种胰岛自身抗体或1型糖尿病风险未增加。
  • 在芬兰,该疫苗与胰岛自身免疫和1型糖尿病风险降低相关。

研究设计与样本

  • TEDDY前瞻性队列研究,随访儿童胰岛自身免疫和1型糖尿病的发生。
  • 2009年10月大规模接种开始时,瑞典和芬兰共有3401名胰岛自身免疫和1型糖尿病高风险儿童接受随访。
  • 接种记录被登记,针对胰岛素、GAD65和胰岛素瘤相关蛋白2的自身抗体在4岁前每季度检测,此后每半年检测。

主要发现

  • 截至2010年8月5日,2009年10月1日观察为胰岛自身抗体或1型糖尿病高风险的3401名儿童中,2413名(71%)接种了Pandemrix®疫苗。
  • 截至2016年7月31日,232名儿童在10岁前出现至少一种胰岛自身抗体,148名出现多种胰岛自身抗体,96名发展为1型糖尿病。
  • 接种儿童出现至少一种胰岛自身抗体的HR为0.75(95%CI 0.55, 1.03),至少两种自身抗体的HR为0.85(95%CI 0.57, 1.26),1型糖尿病的HR为0.67(95%CI 0.42, 1.07)。
  • 在芬兰,接种儿童相比未接种Pandemrix®者,胰岛自身免疫风险为0.47(95%CI 0.29, 0.75),多种自身抗体风险为0.50(95%CI 0.28, 0.90),1型糖尿病风险为0.38(95%CI 0.20, 0.72);瑞典未见此关联。
  • 分析已对混杂因素进行调整。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: During the A/H1N1 2009 (A/California/04/2009) pandemic, mass vaccination with a squalene-containing vaccine, Pandemrix®, was performed in Sweden and Finland. The vaccination was found to cause narcolepsy in children and young adults with the HLA-DQ 6.2 haplotype. The aim of this study was to investigate if exposure to Pandemrix® similarly increased the risk of islet autoimmunity or type 1 diabetes. METHODS: In The Environmental Determinants of Diabetes in the Young (TEDDY) study, children are followed prospectively for the development of islet autoimmunity and type 1 diabetes. In October 2009, when the mass vaccination began, 3401 children at risk for islet autoimmunity and type 1 diabetes were followed in Sweden and Finland. Vaccinations were recorded and autoantibodies against insulin, GAD65 and insulinoma-associated protein 2 were ascertained quarterly before the age of 4 years and semi-annually thereafter. RESULTS: By 5 August 2010, 2413 of the 3401 (71%) children observed as at risk for an islet autoantibody or type 1 diabetes on 1 October 2009 had been vaccinated with Pandemrix®. By 31 July 2016, 232 children had at least one islet autoantibody before 10 years of age, 148 had multiple islet autoantibodies and 96 had developed type 1 diabetes. The risk of islet autoimmunity was not increased among vaccinated children. The HR (95% CI) for the appearance of at least one islet autoantibody was 0.75 (0.55, 1.03), at least two autoantibodies was 0.85 (0.57, 1.26) and type 1 diabetes was 0.67 (0.42, 1.07). In Finland, but not in Sweden, vaccinated children had a lower risk of islet autoimmunity (0.47 [0.29, 0.75]), multiple autoantibodies (0.50 [0.28, 0.90]) and type 1 diabetes (0.38 [0.20, 0.72]) compared with those who did not receive Pandemrix®. The analyses were adjusted for confounding factors. CONCLUSIONS/INTERPRETATION: Children with an increased genetic risk for type 1 diabetes who received the Pandemrix® vaccine during the A/H1N1 2009 pandemic had no increased risk of islet autoimmunity, multiple islet autoantibodies or type 1 diabetes. In Finland, the vaccine was associated with a reduced risk of islet autoimmunity and type 1 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Elding Larsson H, Lynch KF, Lönnrot M, et al. Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children. Diabetologia. 2017. PMID: 28990147. doi:10.1007/s00125-017-4448-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。